Bioceltix S.A.
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells … Read more
Bioceltix S.A. (BCX) - Total Liabilities
Latest total liabilities as of September 2025: zł3.16 Million PLN
Based on the latest financial reports, Bioceltix S.A. (BCX) has total liabilities worth zł3.16 Million PLN as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bioceltix S.A. - Total Liabilities Trend (2018–2024)
This chart illustrates how Bioceltix S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bioceltix S.A. Competitors by Total Liabilities
The table below lists competitors of Bioceltix S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Frequency Therapeutics Inc
NASDAQ:KRRO
|
USA | $62.52 Million |
|
Assertio Therapeutics Inc
NASDAQ:ASRT
|
USA | $213.97 Million |
|
YEAH1 Group Corp
VN:YEG
|
Vietnam | ₫643.42 Billion |
|
Xaar plc
PINK:XAARF
|
USA | $16.36 Million |
|
Honghua Group Limited
F:4HB
|
Germany | €9.06 Billion |
|
PetroShale Inc
OTCQB:PSHIF
|
USA | $102.50 Million |
|
Bien Sparebank ASA
OL:BIEN
|
Norway | Nkr5.29 Billion |
|
Seoyon Co Ltd
KO:007860
|
Korea | ₩2.05 Trillion |
Liability Composition Analysis (2018–2024)
This chart breaks down Bioceltix S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioceltix S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioceltix S.A. (2018–2024)
The table below shows the annual total liabilities of Bioceltix S.A. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł3.44 Million | +51.47% |
| 2023-12-31 | zł2.27 Million | -9.35% |
| 2022-12-31 | zł2.50 Million | +13.93% |
| 2021-12-31 | zł2.20 Million | +48.44% |
| 2020-12-31 | zł1.48 Million | +11.81% |
| 2019-12-31 | zł1.32 Million | -23.41% |
| 2018-12-31 | zł1.73 Million | -- |